{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:16:06Z","timestamp":1794024966739,"version":"4.8.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03503-6","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:40:04Z","timestamp":1788536404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Regulatory and Quality Considerations of Antibody-drug Conjugates"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7569-1842","authenticated-orcid":false,"given":"Karen J.","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8810-7761","authenticated-orcid":false,"given":"Morris","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"2746","key":"3503_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/bmj.2.2746.353","volume":"2","author":"P Ehrlich","year":"1913","unstructured":"Ehrlich P. Address in pathology, on chemiotherapy. Br Med J. 1913;2(2746):353\u20139. https:\/\/doi.org\/10.1136\/bmj.2.2746.353.","journal-title":"Br Med J"},{"issue":"5","key":"3503_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0529-7","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody\u2013drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015\u201335. https:\/\/doi.org\/10.1007\/s12325-017-0529-7.","journal-title":"Adv Ther"},{"issue":"1","key":"3503_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ar700108f","volume":"41","author":"RVJ Chari","year":"2008","unstructured":"Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98\u2013107. https:\/\/doi.org\/10.1021\/ar700108f.","journal-title":"Acc Chem Res"},{"issue":"5","key":"3503_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3503_CR5","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters C, Brown S. Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225. https:\/\/doi.org\/10.1042\/BSR20150089.","journal-title":"Biosci Rep"},{"issue":"20","key":"3503_CR6","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0789.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3503_CR7","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490\u20136.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3503_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/sj.leu.2401663","volume":"14","author":"ID Bernstein","year":"2000","unstructured":"Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia. 2000;14(3):474\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2401663.","journal-title":"Leukemia"},{"issue":"24","key":"3503_CR9","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, et al. Phase III study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with AML (SWOG S0106). Blood. 2013;121(24):4854\u201360. https:\/\/doi.org\/10.1182\/blood-2013-01-466706.","journal-title":"Blood"},{"key":"3503_CR10","unstructured":"U.S. Food and Drug Administration. Wyeth Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application for MYLOTARG. Federal Register, Docket No. FDA-2011-N-0828. 2011. Published Document: 2011-30473 (76 FR 72955)."},{"issue":"9825","key":"3503_CR11","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de novo AML (ALFA-0701). Lancet. 2012;379(9825):1508\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(12)60485-1.","journal-title":"Lancet"},{"issue":"7","key":"3503_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778\u201384. https:\/\/doi.org\/10.1038\/nbt832.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"3503_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1021\/bc700432f","volume":"19","author":"SC Alley","year":"2008","unstructured":"Alley SC, et al. Contribution of linker stability to ADC efficacy. Bioconjug Chem. 2008;19(4):759\u201365. https:\/\/doi.org\/10.1021\/bc700432f.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"3503_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/bc060021d","volume":"17","author":"SC Jeffrey","year":"2006","unstructured":"Jeffrey SC, et al. Development and properties of beta-glucuronide linkers for ADCs. Bioconjug Chem. 2006;17(3):831\u201340. https:\/\/doi.org\/10.1021\/bc060021d.","journal-title":"Bioconjug Chem"},{"key":"3503_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","volume":"64","author":"EL Sievers","year":"2013","unstructured":"Sievers EL, Senter PD. Antibody\u2013drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15\u201329. https:\/\/doi.org\/10.1146\/annurev-med-050311-201823.","journal-title":"Annu Rev Med"},{"key":"3503_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.011","volume":"181","author":"PA Trail","year":"2018","unstructured":"Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer. Pharmacol Ther. 2018;181:126\u201342. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.07.011.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"3503_CR17","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li H, Gou L, Wang Y. Antibody-drug conjugates: recent advances in payloads. Acta Pharm Sin B. 2023;13(10):4025\u201359. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.015.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"3503_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, et al. Bystander killing effect of trastuzumab deruxtecan. Cancer Sci. 2016;107(7):1039\u201346. https:\/\/doi.org\/10.1111\/cas.12966.","journal-title":"Cancer Sci"},{"issue":"8","key":"3503_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula JR, et al. Site-specific conjugation improves therapeutic index. Nat Biotechnol. 2008;26(8):925\u201332. https:\/\/doi.org\/10.1038\/nbt.1480.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"3503_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","volume":"20","author":"P Strop","year":"2013","unstructured":"Strop P, et al. Location matters: site of conjugation modulates ADC stability. Chem Biol. 2013;20(2):161\u20137. https:\/\/doi.org\/10.1016\/j.chembiol.2013.01.010.","journal-title":"Chem Biol"},{"issue":"2","key":"3503_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/bc5004982","volume":"26","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bertozzi CR. Site-specific antibody\u2013drug conjugates. Bioconjug Chem. 2015;26(2):176\u201392. https:\/\/doi.org\/10.1021\/bc5004982.","journal-title":"Bioconjug Chem"},{"key":"3503_CR22","doi-asserted-by":"crossref","unstructured":"McKertish CM, Kayser V. Biomedicines. 2021;9(8):872. 10.3390.","DOI":"10.3390\/biomedicines9080872"},{"key":"3503_CR23","unstructured":"FDA CDER. Expedited programs for serious conditions\u2014drugs and biologics. Guidance for Industry. 2014. Docket No. FDA-2013-D-0575. Available from: www.fda.gov."},{"issue":"6","key":"3503_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","volume":"4","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, et al. A 25-year experience of FDA accelerated approval. JAMA Oncol. 2018;4(6):849\u201356. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5618.","journal-title":"JAMA Oncol"},{"key":"3503_CR25","unstructured":"ICH HARMONISED TRIPARTITE GUIDELINE Q8(R2). Pharmaceutical Development. Current Step 4 version dated August 2009. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR26","unstructured":"ICH HARMONISED TRIPARTITE GUIDELINE Q9(R1). Quality Risk Management. Final version Adopted on 18 Jan 2023. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR27","unstructured":"ICH HARMONISED TRIPARTITE GUIDELINE Q10. Pharmaceutical Quality System. Current Step 4 version dated 4 June 2008. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR28","doi-asserted-by":"publisher","unstructured":"Kaplon H, et al. Antibodies to watch in 2024.\u00a0mAbs.\u00a02024;16(1):2281176. https:\/\/doi.org\/10.1080\/19420862.2023.2281176","DOI":"10.1080\/19420862.2023.2281176"},{"issue":"7","key":"3503_CR29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, et al. Trastuzumab deruxtecan in HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"16","key":"3503_CR30","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, et al. Sacituzumab govitecan in metastatic TNBC. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"issue":"12","key":"3503_CR31","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"JE Rosenberg","year":"2021","unstructured":"Rosenberg JE, et al. Enfortumab vedotin in urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"key":"3503_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","volume":"69","author":"JM Lambert","year":"2018","unstructured":"Lambert JM, Berkenblit A. Antibody\u2013drug conjugates for cancer treatment. Annu Rev Med. 2018;69:191\u2013207. https:\/\/doi.org\/10.1146\/annurev-med-061516-121357.","journal-title":"Annu Rev Med"},{"key":"3503_CR33","doi-asserted-by":"publisher","unstructured":"Beck A, Reichert JM. Marketing approval of antibody\u2013drug conjugates.\u00a0mAbs.\u00a02014;6(1):15\u201317. https:\/\/doi.org\/10.4161\/mabs.27089","DOI":"10.4161\/mabs.27089"},{"issue":"1","key":"3503_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, et al. Antibody\u2013drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0582.","journal-title":"Mol Cancer Res"},{"issue":"11","key":"3503_CR35","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1650-7","volume":"32","author":"N Jain","year":"2015","unstructured":"Jain N, et al. Current ADC landscape and future directions. Pharm Res. 2015;32(11):3526\u201340. https:\/\/doi.org\/10.1007\/s11095-015-1650-7.","journal-title":"Pharm Res"},{"issue":"5","key":"3503_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaia N. Nat Rev Drug Discov. 2017;16(5):315337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"key":"3503_CR37","unstructured":"FDA Guidance for Industry. Clinical Pharmacology Considerations for Antibody-Drug Conjugates March 2024. Docket No. FDA-2021-D-1051. Available from: www.fda.gov. Accessed 10 Aug 2026."},{"key":"3503_CR38","unstructured":"European Medicines Agency post-authorisation procedural advice for users of the centralised procedure. 15 January 2026; EMEA-H-19984\/03 Rev. 116."},{"key":"3503_CR39","unstructured":"ICH Harmonized Tripartite Guideline S6(R1): Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals and Addendum. 2011. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR40","unstructured":"ICH Harmonized Tripartite Guideline S9: Nonclinical Evaluation for Anticancer Pharmaceuticals, Step 4. 2009. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR41","unstructured":"ICH Harmonized Tripartite Guideline S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals, Questions and Answers, Step 4. 2018. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR42","unstructured":"ICH Harmonized Tripartite Guideline M4: Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use. Step 4. 2004. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR43","unstructured":"Food and Drug Administration. Prescription Drug User Fee Act (PDUFA) VII: Fiscal Years 2023\u20132027, 6th Reauthorization. Available from: www.fda.gov. Accessed 10 Aug 2026."},{"key":"3503_CR44","unstructured":"Food and Drug Administration Guidance for Industry, Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products, Draft. 2023."},{"key":"3503_CR45","unstructured":"Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions \u2013Drugs and Biologics. 2014."},{"key":"3503_CR46","unstructured":"European Medicines Agency. Guidance for applicants seeking access to PRIME scheme. 2024. Available from: www.ema.europa.eu. Accessed 10 Aug 2026."},{"key":"3503_CR47","unstructured":"European Medicines Agency. Accelerated Assessment Pursuant to Article 14 (9) of Regulation (EC) No 726\/2004. Available from: www.ema.europa.eu. Accessed 10 Aug 2026."},{"key":"3503_CR48","unstructured":"European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement Regulation (EC) No 507\/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004. 2016. Available from: www.ema.europa.eu. Accessed 10 Aug 2026."},{"key":"3503_CR49","unstructured":"Japan Ministry of Health, Labour and Welfare (MHLW). Strategy of SAKIGAKE. 2014. Available from: pmda.go.jp. Accessed 10 Aug 2026."},{"key":"3503_CR50","unstructured":"Japan Pharmaceuticals and Medical Devices Agency (PMDA). Guidance for Conditional and Time-Limited Approval for Regenerative Medical Products. 2024. Available from: pmda.go.jp. Accessed 10 Aug 2026."},{"key":"3503_CR51","unstructured":"Health Canada. Guidance for Industry - Priority Review of Drug Submissions. 2009. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents.html."},{"key":"3503_CR52","unstructured":"Health Canada. Guidance Document: Notice of Compliance with Conditions (NOC\/c). 2016. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents.html."},{"key":"3503_CR53","unstructured":"Australian Therapeutic Goods Administration (TGA). Meeting the eligibility criteria for priority review determination. 2024. Available from: https:\/\/www.tga.gov.au\/resources\/guidance."},{"key":"3503_CR54","unstructured":"Australian Therapeutic Goods Administration (TGA). Provisional determination eligibility criteria, Including supporting documentation. 2021. Available from: https:\/\/www.tga.gov.au\/resources\/guidance."},{"key":"3503_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.01.014","author":"H Saber","year":"2015","unstructured":"Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol. 2015. https:\/\/doi.org\/10.1016\/j.yrtph.2015.01.014.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3503_CR56","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1535-7163.MCT-24-0087","volume":"23","author":"HD Neff-LaFord","year":"2024","unstructured":"Neff-LaFord HD, Carratt SA, Carosino C, et al. The Vedotin Antibody-Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles. Mol Cancer Ther. 2024;23:1483\u201393.","journal-title":"Mol Cancer Ther"},{"key":"3503_CR57","unstructured":"Food and Drug Administration Guidance for Industry (draft) on \u201cStreamlined Nonclinical Safety Studies for Biologics and Conjugated Products\u201d. 2026. Available from: www.fda.gov. Accessed 10 Aug 2026."},{"key":"3503_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/antib10020015","volume":"10","author":"JE Fisher Jr.","year":"2021","unstructured":"Fisher JE Jr. Considerations for the nonclinical safety evaluation of antibody\u2013drug conjugates. Antibodies (Basel). 2021;10:15. https:\/\/doi.org\/10.3390\/antib10020015.","journal-title":"Antibodies (Basel)"},{"key":"3503_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:51.","journal-title":"J Hematol Oncol"},{"key":"3503_CR60","unstructured":"Food and Drug Administration: Roadmap to Reducing Animal Testing in Preclinical Safety Studies. 2025. Available from: www.fda.gov. Accessed 10 Aug 2026."},{"key":"3503_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, et al. Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:51. https:\/\/doi.org\/10.1186\/s13045-025-01704-3.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3503_CR62","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0529-7","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody\u2013drug conjugates (ADCs) for personalized treatment of solid tumors. Adv Ther. 2017;34(5):1015\u201335. https:\/\/doi.org\/10.1007\/s12325-017-0529-7.","journal-title":"Adv Ther"},{"issue":"1","key":"3503_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody\u2013drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0582.","journal-title":"Mol Cancer Res"},{"key":"3503_CR64","unstructured":"ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. 2009. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR65","unstructured":"ICH Harmonised Tripartite Guideline Q9: Quality Risk Management. 2005. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR66","unstructured":": Development and Manufacture of Drug Substances. 2012. Available from: www.ich.org. Accessed 10 Aug 2026."},{"issue":"12","key":"3503_CR67","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cbic.201402154","volume":"15","author":"SB Sun","year":"2014","unstructured":"Sun SB, Schultz PG, Kim CH. Therapeutic applications of an expanded genetic code. Chembiochem. 2014;15(12):1721\u20139. https:\/\/doi.org\/10.1002\/cbic.201402154.","journal-title":"Chembiochem"},{"key":"3503_CR68","unstructured":"ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System. 2008. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR69","unstructured":"ICH Harmonised Tripartite Guideline Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. 1999. Available from: www.ich.org. Accessed 10 Aug 2026."},{"issue":"2","key":"3503_CR70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","volume":"20","author":"P Strop","year":"2013","unstructured":"Strop P, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161\u20137. https:\/\/doi.org\/10.1016\/j.chembiol.2013.01.010.","journal-title":"Chem Biol"},{"key":"3503_CR71","unstructured":"ISPE Baseline\u00ae Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP).\u00a0International Society for Pharmaceutical Engineering; 2010."},{"issue":"8","key":"3503_CR72","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula JR, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925\u201332. https:\/\/doi.org\/10.1038\/nbt.1480.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"3503_CR73","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/bc5004982","volume":"26","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bertozzi CR. Site-specific antibody\u2013drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015;26(2):176\u201392. https:\/\/doi.org\/10.1021\/bc5004982.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"3503_CR74","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/abt\/tbaa027","volume":"3","author":"A Sadiki","year":"2020","unstructured":"Sadiki A, et al. Site-specific conjugation of native antibody. Antibody Ther. 2020;3(4):271\u201384. https:\/\/doi.org\/10.1093\/abt\/tbaa027.","journal-title":"Antibody Ther"},{"key":"3503_CR75","doi-asserted-by":"publisher","unstructured":"Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in antibody\u2013drug conjugate development.\u00a0mAbs.\u00a02013;5(5):637\u2013654. https:\/\/doi.org\/10.4161\/mabs.25720","DOI":"10.4161\/mabs.25720"},{"issue":"4","key":"3503_CR76","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1021\/bc700432f","volume":"19","author":"SC Alley","year":"2008","unstructured":"Alley SC, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(4):759\u201365. https:\/\/doi.org\/10.1021\/bc700432f.","journal-title":"Bioconjug Chem"},{"key":"3503_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0284198","volume":"14","author":"W Yu","year":"2023","unstructured":"Yu W, Ramprasad MP, Pal M, Chen C, et al. Analytical comparability to evaluate impact of manufacturing changes of ARX788, an anti-HER2 ADC in late-stage clinical development. PLoS ONE. 2023;14:1\u201321. https:\/\/doi.org\/10.1371\/journal.pone.0284198.","journal-title":"PLoS ONE"},{"issue":"2","key":"3503_CR78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/abt\/tbaf005","volume":"8","author":"W Lili","year":"2025","unstructured":"Lili W, et al. Fundamental Properties and Principal Areas of Focus in Antibody-Drug Conjugates Formulation Development. Antib Ther. 2025;8(2):99\u2013100. https:\/\/doi.org\/10.1093\/abt\/tbaf005.","journal-title":"Antib Ther"},{"key":"3503_CR79","unstructured":"ICH Harmonised Tripartite Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. 2019. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR80","doi-asserted-by":"publisher","unstructured":"Wakanar AA, Feeney MB, Rivera J, et al. Analytical methods for physicochemical characterization of antibody drug conjugates.\u00a0mAbs.\u00a02011;3(2):161\u2013172. https:\/\/doi.org\/10.4161\/mabs.3.2.14960","DOI":"10.4161\/mabs.3.2.14960"},{"key":"3503_CR81","unstructured":"ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. 2003. Available from: www.ich.org. Accessed 10 Aug 2026."},{"key":"3503_CR82","unstructured":"Food and Drug Administration. Q1A(R2) stability testing of new drug substances and products (Adopted ICH Guidance). 2003. Available from: www.fda.gov. Accessed 10 Aug 2026."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03503-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:04:47Z","timestamp":1793372687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":82,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3503"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03503-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to add the collection title as the sub-category and to include the editorial responsibility information above authors affiliation.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"262"}}